There are some big caveats on obesity though, IMO:
- To state the obvious, Race would have to prove it could work as an anti-obesity agent through clinical research.
- Then, it's a different game to get it approved. FDA may eagerly approve salvage drugs for patients in advanced cancer stage, given it is a life-or-death situation which outweights any potential risks for patients. In comparison, obesity is not life-threatening and would be scrutinised for side effects. Back in 2006, Sanofi got burnt with Acomplia.
Case: Accomplia/Rimonabant is a a cannabinoid receptor antagonist that blocks the signals of hunger. The drug worked very well and was was approved, expected to be a blockbuster, but some patients anecdotically reported an increase in depression/suicidal thoughts. which pushed FDA and other regulators to withdraw approval. Acomplia when from blockbuster to bust.
https://www.fiercepharma.com/special-report/acomplia-pharma-s-biggest-flops
Bisantrene has a totally different acting mechanism compared to Acomplia. Instead of interfering with brain signals it actually meddles with cell/DNA reproduction, which from my unqualified opinion would place it much higher on the scale of risks.
IMHO and would be great to have an expert opinion on this. Dr T perhaps?
- Forums
- ASX - By Stock
- RAC
- Pillar 1 - FTO (new thread)
Pillar 1 - FTO (new thread), page-36
-
- There are more pages in this discussion • 2,907 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.84 |
Change
-0.025(1.34%) |
Mkt cap ! $313.3M |
Open | High | Low | Value | Volume |
$1.89 | $1.91 | $1.81 | $257.6K | 138.9K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 26825 | $1.84 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.90 | 759 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 7989 | 1.815 |
1 | 14750 | 1.810 |
1 | 800 | 1.800 |
2 | 2000 | 1.780 |
1 | 10000 | 1.770 |
Price($) | Vol. | No. |
---|---|---|
1.910 | 2500 | 1 |
1.915 | 1000 | 1 |
1.920 | 10000 | 1 |
1.950 | 3982 | 1 |
1.960 | 9500 | 1 |
Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |
The Watchlist
FHE
FRONTIER ENERGY LIMITED
Adam Kiley, CEO
Adam Kiley
CEO
SPONSORED BY The Market Online